Objective To conduct a meta-analysis of the efficacy and safety of 225Ac-PSMA-617 in the
treatment of metastatic castration-resistant prostate cancer based on existing clinical …

Background Targeted radionuclide therapy with Actinium-225-labeled prostate-specific
membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality …

Purpose This review discusses the current state of prostate-specific membrane antigen
(PSMA)-based alpha therapy of metastatic castration-resistant prostate cancer (mCRPC) …

The use of 225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand
therapy (RLT), either as monotherapy or in combination with 177Lu, is a promising therapy …

Background: Actinium-225 (Ac-225) labelled PSMA RLT has been tested recently in
metastatic castration-resistant prostate cancer (mCRPC), with encouraging results. Ac-225 …

The high energy of α emitters, and the strong linear energy transfer that goes along with it,
lead to very efficient cell killing through DNA damage. Moreover, the degree of oxygenation …

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment
of prostate cancer (PCa). Actinium-225 (225 Ac), a potent alpha-emitting radionuclide, may …

For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC)
who do not respond to [177Lu] Lu-PSMA therapy, there are limited treatment options …

Prostate-specific membrane antigen (PSMA), overexpressed in prostate cancer, has
become a popular target for radionuclide-based theranostic applications in the advanced …

Background Targeted radionuclide therapy with Actinium‐225‐labeled prostate‐specific
membrane antigen agents (225Ac‐PSMA) is currently being studied in clinical trials for …